Nvidia, Novo Nordisk Expand AI in Drug Discovery

Nvidia and Novo Nordisk have formed a major partnership to accelerate drug discovery and development using artificial intelligence, with a focus on Denmark’s Gefion AI supercomputer. The collaboration seeks to build customized AI models, simulation environments, and digital twins to optimize early-stage clinical research and streamline R&D workflows. Novo Nordisk researchers will leverage Nvidia’s platforms, including BioNeMo, Nim, and Omniverse, to develop single-cell models, design drug-like molecules, and create biomedical large language models capable of analyzing scientific literature for gene-disease correlations. This initiative enhances Novo Nordisk's work with the Danish Centre for AI Innovation and significantly expands Nvidia’s reach beyond semiconductors. Executives from both companies emphasize the potential for unprecedented efficiency and efficacy in pharmaceutical R&D. Nvidia also announced a separate partnership with IQVIA to advance global AI-driven clinical research and commercialization.